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Opinion Statement
The conceptual shift of our understanding of migraine from a vascular disorder to a
brain disorder has dramatically altered the approach to the development of new med-
icines in the field. Current pharmacologic treatments of acute migraine consist of non-
specific and relatively specific agents. Migraine-specific drugs comprise two classes,
the ergot alkaloid derivatives and the triptans, serotonin 5-HT1B/1D receptor agonists.
The ergots, consisting of ergotamine and dihydroergotamine (DHE), are the oldest spe-
cific antimigraine drugs available and are considered relatively safe and effective. Er-
gotamine has been used less extensively because of its adverse effects; DHE is better
tolerated. The triptan era, beginning in the 1990s, was a period of considerable
change, although these medicines retained vasoconstrictor actions. New methods of
delivering older drugs include orally inhaled DHE and the transdermal formulation of
sumatriptan, both currently under study. Novel medicines being developed are targeted
at neural sites of action. Serotonin 5-HT1F receptor agonists have proven effective in
phase II studies and have no vascular actions. Calcitonin gene-related peptide (CGRP)
receptor antagonists are another promising nonvasoconstrictor approach to treating
acute migraine. Olcegepant (BIBN4096BS) and telcagepant (MK-0974) have been
shown to be safe and effective in phase I, II, and (for telcagepant) phase III clinical
trials. Other targets under investigation include glutamate (AMPA/kainate), TRPV1,
prostanoid EP4, and nitric oxide synthase. With new neural targets and the potential
for therapeutic advances, the next era of antimigraine medications is near.
Introduction
Migraine is a common and disabling neurologic dis-
order with complex neurobiology that has fascinat-
ed physicians and scientists for centuries. The
pathogenesis was once considered vascular, and this
vascular theory gained momentum as a conse-
quence of experimental work done by Harold Wolff
and colleagues [1]. They showed that infusions of
intravenous ergotamine, a vasoconstrictor, resulted
in a decrease in both headache and temporal pulsa-
tions in some patients. Conversely, dihydroergota-
mine has been shown to inhibit second-order
trigeminal neurons in the trigeminocervical complex
[2], suggesting that these drugs have a neural mode
of action.We now know that although blood vessel changes
may occur during attacks, they are not the inciting
mechanism of an attack, and the vessel caliber does
not change in parallel with therapy [3]. Premonitory
symptoms such as fatigue, concentration impairment,
and mood change can occur a day before the head-
ache, suggesting brain involvement at an early stage
of the attack. Typical attacks are characterized by the
perception of throbbing head pain aggravated by
movement and accompanied by nausea, vomiting, or
both. The broad dysfunction in sensory processing
during an acute attack manifests itself clinically as
photophobia, phonophobia, or osmophobia. Taken
together, migraine is best explained by a dysfunction
in the neuromodulatory structures of the brainstem,
evidenced by PET studies that have shown an area of
activation in the dorsolateral pons [4]. Ultimately,
the recognition of migraine as a brain disorder has
been important in understanding the disease and sug-
gesting novel neural targets.
Types of acute migraine agents
Acute migraine treatments consist of migraine-specific
and nonspecific agents, although it must be acknowl-
edged that the specificity is relative, as triptans are also
excellent treatments for cluster headache. Nonspecific
agents such as NSAIDs, acetaminophen (paracetamol),
and aspirin are effective [5], Class I], but gastrointesti-
nal effects can often limit their use. Opioids may be
useful for some patients, but their use should be re-
stricted because of the potential for medication over-
use headache and addiction. Compounds containing
butalbital have little obvious utility. Ergotamine and
DHE are migraine-specific medications with a long
history of effectiveness, and the introduction of the
triptans, serotonin 5-HT1B/1D receptor agonists, was
revolutionary. Sumatriptan was the first available trip-
tan and was followed by six others: rizatriptan, eletrip-
tan, almotriptan, zolmitriptan, naratriptan, and
frovatriptan. These are highly effective medications
that have transformed the lives of many patients suf-
fering with migraines [6, Class I]. The triptans have en-
hanced clinical practice, our basic pharmacologic
understanding, and health care delivery systems. Nev-
ertheless, only one third of patients in clinical trials are
pain-free 2 h after taking a triptan orally, so novel
treatment options are needed [6, Class I].
Aims of acute migraine treatment
Asmigraine contributes tosick days, loss ofproductivity,
andemergencyroomvisits,thereisconsiderableneedfor
improvement in medicines to control acute attacks. The
effectiveness of acute treatments can be measured clini-
cally using migraine diaries. In randomized, double-
blind, placebo-controlled trials, optimal acute migraine
treatments are determined by well-established efficacy,
tolerability,and safetyprofilesdetermined by end points
introduced during the triptans era [7]. For acute treat-
ment, patients ultimately want rapid pain relief that is
long-lasting. Perhaps the most patient-centered measure
is the composite end point known as sustained freedom
from pain with no adverse events (SNAE), which is de-
finedasfreedomfrompainwithin2h,withnouseofres-
cue medication or headache recurrence within a
minimumperiodof24handnoadverseevents[8].With
these aims in mind, treatment can potentially transform
the quality of life of the migraine sufferer and minimize
the societal impact of the disorder.
Treatment
Pharmacologic treatment
Emerging therapies
& The development of new compounds is long overdue. Though the
triptanerahasprofoundlyexpandedthetherapeuticarmamentariumin
clinical practice, inadequate response, tolerability, and contraindica-
tions to their use in patients with a history of stroke, myocardial in-
farction,orcoronaryartery disease risk equivalents remain major issues
(though probably overestimated). For this reason, compounds that are
not vasoactive may hold the promise of wider therapeutic potential.
2 HeadacheAlthough the pharmacotherapy of migraine has advanced in parallel
withourunderstandingofthepathophysiologyofthedisease,itisclear
that more experimental work is necessary to identify new targets and to
develop more efficacious antimigraine compounds.
& Though human migraine models have been paramount in proving
efficacy and tolerability, much work remains in deciphering the re-
lationship between the agents of provocation (eg, nitric oxide
donors, CGRP, 5-HT, or prostaglandins) the cascade of events, and
their mechanistic role. As migraine is clearly a genetic disorder, the
use of genome-wide studies and pharmacogenetics may be fruitful.
Despite these challenges, the clinical use of nonvasoconstrictor
antimigraine compounds is near.
& This article aims to review investigational compounds and devices
(Table 1) currently undergoing clinical trials for acute migraine
attacks. The targets reflect our current understanding of the essen-
tially neural basis of migraine.
Serotonin receptor agonists
Seven families of 5-HT receptors have been identified. The 5-HT1
receptors consist of at least five receptor subtypes and represent the
largest subfamily. Migraine patients have low central and interictal 5-
HT plasma levels and increased levels and release of a major 5-HT
metabolite, 5-hydroxyindole acetic acid, 5H1AA, during acute attacks
[9]. Based on these observations of 5-HT metabolism, the potent 5-
HT1B/1D receptor agonists were developed. The trigeminal ganglion
and the free trigeminal nerve fibers contain mainly 5-HT1D receptors,
whereas the small meningeal vessels contain mainly 5-HT1B receptors.
Triptans may exert their effects through presynaptic inhibition of the
peripheral trigeminovascular neurons or through central action along
the trigeminonociceptive pathways [6]. Though earlier events lead to
the initiation of an attack, activation of 5-HT1B/1D and 5-HT1F recep-
Table 1. Emerging therapies for acute migraine
Compounds Treatment class Clinical phase
COL-144 5-HT1F receptor agonist Phase II–complete
Telcagepant (MK-0974) CGRP receptor antagonist Phase III–complete
BI 44370 CGRP receptor antagonist Phase II–complete
BGG492 AMPA receptor antagonist Phase II
Tezampanel (LY-293558) AMPA and kainate receptor antagonist Phase II
LY466195
a GLUK5 kainate receptor antagonist Phase II
SB-705498 TRPV1 receptor antagonist Phase II–complete
NXN-188 Neuronal nitric oxide synthase (nNOS) inhibition & 5-HT1B/D agonist Phase II
GW274150 Inducible nitric oxide synthase inhibition Phase II–complete
BGC20-1531 Prostanoid EP4 receptor antagonist Phase II, phase I
aNot yet listed on the ClinicalTrials.gov website
AMPA α-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid, CGRP calcitonin gene-related peptide, TRPV1 transient receptor potential
vanilloid subfamily member 1
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system, possibly by blocking the release of calcitonin gene-related
peptide (CGRP), as opposed to vasoconstriction, which is likely a
parallel phenomenon [10].
The 5-HT1D receptor agonists are potent inhibitors of dural neurogenic
protein plasma extravasation without any vasoconstrictor effects. There-
fore, it is conceivable that the 5-HT1D receptor agonists may be potential
therapies. Unfortunately, PNU-142633, a 5-HT1D agonist, was ineffective
in clinical studies. In retrospect, this result may have been predicted, as
PNU-142633 is a relatively weak agonist when compared with suma-
triptan, and it also has poor blood-brain barrier penetration [11]. It
remains questionable whether more potent 5-HT1D agonists will be the
answer, as dural protein plasma extravasation is not a major player in
migraine pathogenesis [12].
The 5-HT1F receptor is a potential neural target distributed in the tri-
geminal ganglion and the trigeminal nucleus caudalis. 5-HT1F receptor
activation inhibits trigeminal nucleus Fos activation, a marker of neu-
ronal activation, and neuronal firing without vasoconstrictor effects.
When tested, the potent 5-HT1F agonist, LY-334370 was effective in acute
migraine, but at doses with adverse effects on the central nervous system
[13]. Unfortunately, its development was halted by nonhuman toxicity
unrelated to the migraine mechanism. Another 5-HT1F receptor agonist,
COL-144, is orally bioavailable, and a placebo-controlled, dose-ranging
phase II study was positive [14].
Calcitonin gene-related peptide receptor antagonists
Beyond the triptans, the CGRP receptor antagonists seem to be the most
promising non-vasoconstrictor acute migraine treatments. CGRP is a
neuropeptide product produced by alternative RNA splicing of the cal-
citonin gene. CGRP receptors are found on meningeal blood vessels,
trigeminal ganglion and afferents, in the periaqueductal gray, and in
other areas of the brain associated with migraine [15]. Stimulation of the
trigeminal ganglion can result in elevations of CGRP and substance P
[16], but only CGRP was significantly elevated in the external jugular
veins in patients during an acute attack of migraine [17]. These obser-
vations contributed to the development of CGRP receptor antagonists
(olcegepant [BIBN4096BS, given intravenously] and telcagepant [MK-
0974, given orally], also called the gepants) in the treatment of acute
migraine attacks.
Olcegepant has been shown to be effective and well tolerated in phase
II trials [18], and for telcagepant phase III clinical trials for acute treat-
ment [19￿￿]. In a recent large, multicenter, randomized controlled trial
of telcagepant (150 mg or 300 mg) versus zolmitriptan (5 mg) or pla-
cebo, 300 mg of telcagepant was more effective than placebo for pain
freedom, pain relief, and absence of photophobia, phonophobia, and
nausea. The efficacies of 300 mg of telcagepant and 5 mg of zolmitriptan
were similar, and both were more effective than 150 mg of telcagepant.
Unfortunately, a preventive study of telcagepant in migraine resulted in
elevated liver transaminases in some participants, so dosing restrictions
may be required in clinical practice.
4 HeadacheGlutamate receptor antagonists
Glutamate is the most important excitatory neurotransmitter, and it
plays a pivotal role in conveying sensory and nociceptive information in
the brain and the spinal cord [20￿]. Glutamate acts through ionotropic
glutamate receptors (iGluR) (ligand-gated channels) and G-protein
coupled metabotropic receptor families. The iGluR receptors are divided
in three subtypes: N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-
5-methyl-4-isoazolepropionic acid (AMPA), and kainate. Glutamate
receptors are distributed within the pain relay structures important for
migraine pathophysiology. In addition, glutamate neurons in the tri-
geminal ganglia mostly express 5-HT1B/1D/1F receptors, which have been
proposed to modulate glutamate release [21]. Furthermore, the excit-
atory neurotransmitter has been implicated in migraine pathophysiolo-
gy, with key roles in trigeminovascular activation, central sensitization,
and cortical spreading depression (CSD) [22].
Nonselective blockade of AMPA and kainate receptors with 6-cyano-7-
nitroquinoxaline-2,3-dione (CNQX) has been shown to block trigemi-
nocervical complex cell firing in response to electrical stimulation of
dural structures in rats [23]. When tested in a small clinical trial, LY-
293558, an AMPA and kainate receptor antagonist, and sumatriptan
were both effective in treating headache and met all primary end points
when compared with placebo [24]. LY-293558, now named tezampanel,
has been studied in phase II trials. In a recent experiment with a model of
neurogenic vasodilatation (a model involving reproducible vasodilata-
tion in response to CGRP release after electrical stimulation of the dura
mater around the middle meningeal artery), iGluR5 receptor activation
inhibited dural vasodilatation, suggesting that the kainate receptor an-
tagonist may exert antinociceptive effects centrally [25]. Following this
rationale, LY466195, a GLUK5 kainate receptor antagonist, may be a
suitable compound. Another glutamate receptor blocker, BGG492, tar-
gets AMPA subtypes and is undergoing phase II clinical trials. There is
evidence for a role for the AMPA receptor in nociceptive trigeminovas-
cular transmission, as blockade with GYKI 52466 produced a dose-de-
pendent inhibition of trigeminovascular evoked responses in the
trigeminocervical complex of cats [26].
The results from a recent genome-wide association study implicates a
sequence variant on 8q22.1, which is flanked between two genes in-
volved in glutamate homeostasis, in the inheritance of migraine [27￿￿].
The effect was strongest for migraine with aura only, but it was also seen in
the all-migraine group. In essence, it is expected that pharmacologic
approaches targeting glutamate receptors may alter migraine pathogenesis
and reveal a novel nonvasoactive therapeutic approach. An important
general caveat to targeting glutamate receptors is the potential for adverse
effects, given their wide distribution within the central nervous system.
Transient receptor potential vanilloid (TRPV1) receptor
antagonists
The transient receptor potential vanilloid subfamily member 1 (TRPV1)
antagonist, SB-705498, has been investigated in a phase II trial. TRPV1
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ingredient in chili peppers), heat, and acid. They are located in both the
central and peripheral trigeminal system [28]; more specifically, TRPV1
immunoreactivity has been found in 16% of human trigeminal ganglion
cells, with a small proportion of TRPV1 receptors showing colocalization
with CGRP receptors [29]. Inhibition of TRPV1 also has been shown to
prevent and reverse central sensitization [30]. Antimigraine action also
seems plausible, as capsaicin-induced dilatation is inhibited by the CGRP
receptor blockade [31]. However, a study of neurogenic dural dilatation in
ratsusingaselectivebrain-penetrantTRPV1antagonist,A-993610,wasable
to block capsaicin-induced dural dilatation but failed to show an effect on
neurogenic dural dilatation [32]. A potential role for the TRPV1 receptor in
trigeminally mediated sensitization has recently been demonstrated [33],
but of itself it is probably not sufficient to indicate antimigraine potential.
The therapeutic gain is not yet known.
Nitric oxide synthesis inhibition
Nitric oxide (NO) is a gaseous molecule produced from nitric oxide
synthase (NOS). NOS has three different isoforms: endothelial (eNos),
neuronal (nNos), and inducible (iNos). NO regulates arterial diameter in
cerebral and extracerebral vessels and has been implicated in the path-
ogenesis of migraine and other pain states [34]. NO has been proposed
to activate trigeminovascular fibers and thus release CGRP [35].
Historically, vasodilatation induced by glyceryl trinitrate has been
considered the underlying mechanism of its triggering migraine
attacks, but several observations suggest that this may be an epiphe-
nomenon. For one, nitroglycerin provocation triggers premonitory
symptoms in many patients that are similar to those occurring with
spontaneous attacks, and they occur well after any presumably vas-
cular changes [36]. In addition, careful monitoring of cranial vessels
using MR angiography shows that NO-induced vasodilatation is long
resolved when migraine starts [37]. In view of these observations, NO
production blockade has been evaluated as a potential nonvasocon-
strictor treatment option.
The inhibition of trigeminocervical complex Fos expression with NOS
blockade by Nω-nitro-L-arginine methyl ester (L-NAME) has been
demonstrated, suggesting a possible approach to therapy [38]. Previ-
ously, NO synthesis inhibition showed positive results in a small cohort
of patients [39], and GW274150, a highly selective iNOS inhibitor,
showed analgesic effects [40]. Results of a recent randomized, single-
blind, placebo-controlled, adaptive clinical trial failed to demonstrate
efficacy for GW274150 in acute migraine [41]. NXN-188 is an nNOS
inhibitor and a 5-HT1B/1D receptor agonist that was also ineffective in a
previous phase II study [42]. A more recent phase II, multicenter, ran-
domized controlled study of NXN-188 showed positive results, however,
and most adverse events were mild to moderate in severity; none were
serious [43]. This combination may be a logical target, as prolonged
administration of triptans may result in increased expression of nNOS,
CGRP, and cutaneous allodynia, the clinical correlate of central sensiti-
zation, a process that may be reversed by nNOS inhibition [44].
6 HeadacheProstanoid receptor antagonists
BGC20-1531 is a prostanoid EP4 receptor competitive antagonist cur-
rently undergoing phase II trials. Prostaglandin E2 (PGE2) is considered
an important mediator of pain and inflammation, and it may play a role
in migraine pathophysiology. In vitro studies of cultured rat trigeminal
neurons show that prostanoids can induce CGRP release [45]. In addi-
tion, elevated PGE2 levels have been demonstrated in the jugular venous
blood [46] during acute migraine attacks.
PGE2 acts through EP receptors: EP1 and EP3 receptor activation
mediate smooth muscle contraction, whereas EP2 and EP4 receptor ac-
tivation exerts vascular smooth muscle relaxation [47]. EP4 receptors
have been shown to be involved with prostaglandin-induced cerebral
vascular dilatation. As vasodilatation is more likely a parallel phenom-
enon in acute migraine, the EP4 receptor association with pain is likely
to be a consequence of an independent antihyperalgesic effect. An anti-
hyperalgesic effect can be appreciated with an EP4 receptor antagonist in
animal models of inflammatory pain [48].
It is not clear whether EP4 receptor antagonists will be more effective
than nonspecific anti-inflammatory agents used in the treatment of mi-
graine. NSAIDs and acetylsalicylic acid are first-line acute migraine
treatments. They reduce headache by inhibiting cyclo-oxygenase, an en-
zyme that catalyzes the conversion of arachidonic acid to prostaglandin
H2, a precursor to inflammatory mediators, the prostanoids. If proven
effective, however, EP4 receptor antagonist medications may be an im-
portant nonvasoconstrictor treatment option.
New approaches to old drugs
& The ergot alkaloids are old but effective specific antimigraine drugs
that are used worldwide. Ergotamine tartrate (ET) was the first pure
ergot alkaloid to be marketed for migraine treatment. Dihydroer-
gotamine (DHE) was synthesized later, in 1943. Because of problems
with tolerability, the potential for vasoconstriction, the poor bio-
availability of oral formulations, and the modest improvements with
intranasal forms, its clinical use has been limited.
& Likewise, the triptans have transformed the lives of many, but gastro-
paresis, nausea, and vomiting are issues that interfere with absorption.
& In addition to limitations associated with the route of administra-
tion, migraine-specific agents are being tested to determine the re-
sponsiveness to clinical phenotypes. The triptan responsiveness of
allodynia has been examined to some extent with almotriptan [49,
Class I], and the effects of intranasal DHE are under study (Table 2).
It will be interesting to see how these symptoms, thought to be
secondary to migrainous biology, respond to treatment.
& Designing new drug delivery systems for acute treatments has
several advantages. For one, the safety profiles of the triptans and
dihydroergotamine are already well established, so it is possible to
bypass the lengthy preclinical stage and reduce the cost of drug
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older drugs.
Dihydroergotamine
ET is not routinely used in Western clinical practice because of its side-
effect profile [50, Class I–III], but the structural alteration to DHE has
resulted in greater tolerability, and it is more likely to cause venocon-
striction than vasoconstriction. Intravenous DHE is safe and effective for
the treatment of intractable headache [50, Class II]. Its mode of action
may be related to its structural similarities with the biogenic amines and
its relative affinities for serotonin, dopamine, and adrenergic receptors.
Table 2. Old drugs, new approaches for acute migraine
Compounds Treatment class Indications Clinical
phase
New routes
DHE (MAP004) Ergot alkaloid, deliv-
ered by inhalation
– Phase III
Sumatriptan (NP101) 5-HT1B/1D, transder-
mal patch
– Phase III
Sumatriptan (Intraject
needle-free system)
5-HT1B/1D – Phase II
Combination approaches
Rizatriptan and acet-
aminophen (parace-
tamol)
5-HT1B/1D, simple
analgesic
– Phase III–
complete
Rizatriptan and caf-
feine
5-HT1B/1D, adenosine
receptor antagonist
– Phase III–
complete
Pediatric indications
Zolmitriptan 5-HT1B/1D Adolescents Phase III
Sumatriptan and nap-
roxen
5-HT1B/1D and NSAID Adolescents Phase III
Rizatriptan 5-HT1B/1D Children and adolescents Phase III
Associated symptoms
Sumatriptan and nap-
roxen or eletriptan
5-HT1B/1D and NSAID Absorption and gastric transit in and outside of an attack Phase I
DHE (intranasal) Ergot alkaloid Migraine with cutaneous allodynia Phase IV
Rizatriptan 5-HT1B/1D Trigeminal unilateral cranial autonomic symptoms (lacrimation,
eye redness, eyelid edema, nasal congestion or rhinorrhea,
miosis or ptosis, forehead or facial sweating)
Phase IV
Rizatriptan 5-HT1B/1D Rotational motion sickness in migraine patients Active
Devices
Transcranial magnetic
stimulation
Noninvasive device – Phase III
Direct transcranial
stimulation
Non-invasive device – Phase II
DHE dihydroergotamine, NSAID nonsteroidal anti-inflammatory drug
8 HeadacheWhether the primary mode of action is peripheral or central is a subject
of debate, as is its ability to penetrate the blood-brain barrier. Experi-
mentally, DHE has been shown to block neurovascular inflammation in
the trigeminal nerve terminals [51]. Alternatively, a central theory of
action has been proposed: stimulation studies of pain-producing struc-
tures such as the superior sagittal sinus or the middle meningeal artery
result in an increase in the firing rate of the trigeminal nucleus caudalis,
which can be inhibited by intravenous DHE [2] or local (ionophoretic)
administration of ergometrine [52]. In further support of centrally me-
diated actions of DHE, Goadsby and Gundlach [53] directly detected the
putative central sites of action of DHE and the extent to which it enters
the brain through the autoradiographic localization of
3H-DHE-binding
sites in the cat central nervous system, both in vitro and in vivo. In the
spinal cord, specific binding was highest in the dorsal horn, whereas the
strongest specific binding was in seen in the trigeminal nucleus caudalis.
Predictably, the highest specific binding was seen in the midbrain in the
distinct areas of the nucleus raphe dorsalis and, to a lesser extent, in the
ventral periaqueductal gray, consistent with a central theory of the effect
of these medications.
DHEadministeredbytheintranasalroutehasabioavailabilityof40%,a
rate that may be partly due to oropharyngeal deposits [54]. Oral inhaled
DHE(MAP0004)providesanovelrouteofadministration,usinganinhaler
that distributes the drug over a wider pulmonary surface area, therefore
improving pulmonary systemic absorption. In a multicenter, randomized,
double-blind phase III trial, DHE through oral inhalation with the new
device met all primary end points and sustained pain freedom for up
to 48 h, according to the company’s press release [55]. It is conceiv-
able that DHE delivered through inhalation, currently in phase
III clinical trials, is likely to become clinically useful in outpatient
practice.
Triptans
Future developments within this class are largely being explored in
connection with the development of new vehicles of administration.
There are no active clinical investigations of novel triptans.
Combinationapproachesofferconvenience,buttheyarenotmorelikely
to be effective than individual dosing. The oral formulation of sumatriptan
85 mg and naproxen sodium 500 mg is on the market [56,C l a s sI ] ,a n d
other combinations of triptans with caffeine or acetaminophen are being
tested (see Table 2).
New routes of administration are being tested. A transdermal formu-
lation of sumatriptan completed a phase III study, which has not been
completely published; at the most recent Congress of the Interna-
tional Headache Society, the company reported significant improve-
ment over placebo in all key primary end points, with some adverse
events at the patch site [57]. This approach may be practical, as
nausea, vomiting and gastric stasis may limit the absorption of oral
medications. Additional investigational delivery systems for suma-
triptan include a new needle-free subcutaneous delivery system [58].
These alternative routes will be fruitful if they can reach peak plasma
Acute Migraine Therapy: New Drugs and New Approaches Monteith and Goadsby 9concentrations that will allow maximal efficacy with fewer vasocon-
strictor side effects mediated by 5-HT1B.
Pediatric considerations
& Migraine is common in pediatric populations, yet randomized con-
trolled trials are few. Pediatric patients are generally considered to
have less feature-full attacks. Unfortunately, many pharmaceutical
options have not been as rigorously tested in these patients as in
adults.
& Sleep can be one treatment option, but when sleep is not effective, a
simple analgesic may be tried [59].
& One randomized controlled trial of sumatriptan nasal spray versus
placebo in adolescents 12 to 17 years of age suggested that the 20 mg
dose of sumatriptan was the most efficacious and provided the best
tolerability profile [60, Class I].
& In a more recent randomized controlled trial, almotriptan was con-
sidered most efficacious at a dose of 12.5 mg and was well tolerated
[61, Class I]. Several ongoing triptan trials are seeking new indica-
tions in the pediatric population (Table 2). One important aspect of
studies in this age group is the issue of expectation and its control use
in a cross-over design [62].
Emerging devices
Trancranial magnetic stimulation and transcranial
direct current stimulation
Transcranial magnetic stimulation (TMS) and transcranial direct current
stimulation (tDCS) are two devices currently being investigated in clin-
ical trials for treatment of acute migraine attacks. These devices have been
used in other pain conditions, in which brain stimulation techniques
seek to modulate activity in neuronal circuitry implicated in pain pro-
cessing. Defective habituation, expressed as greater than normal ampli-
tude of the evoked response to repeated stimulation, is observed in
migraine, making stimulation devices a logical intervention worthy of
clinical testing [63].
These devices target CSD, the wave of depolarization that travels from
the occipital cortex (usually anteriorly), associated with an initial wave of
hypoperfusion seen in migraine with aura and likely associated with
migraine without aura, in which the aura may be clinically silent [64￿].
TMS is a noninvasive method by which weak electrical currents induce a
magnetic field that generates small electrical currents. The electrical
effects of TMS can be appreciated in an experimental rat model of CSD:
in the study, the wave of neuronal excitation was shown to be blocked by
over 50%, indicating that this may be an effective therapeutic option
[65]. As some propose that CSD may trigger an attack by activating the
trigeminovascular system in experimental models, CSD has been tar-
geted [66]. Its not clear that targeting CSD will be the way forward, based
10 Headacheon clinical trials of tonabersat, a neuronal-glial gap junction inhibitor,
which reduced the aura but not the frequency of headaches in patients
with migraine with aura [67].
Because spontaneous attacks may be initiated in the brainstem, deep
neuromodulatory brainstem structures may be an alternative target site.
A randomized, double-blind, parallel-group, sham-controlled trial
of single-pulse TMS for acute treatment of migraine with aura showed
pain-free response rates at 2 h and sustained pain-free responses both
at 24 h and 48 h after treatment [68]. The application of low-intensity
current to the cerebral cortex using tDCS has been investigated and is
now in phase II trials using tDCS ve r s u ss h a mt D C Si np a t i e n t sw i t h
migraine with or without aura and those with chronic migraine [69].
If proven effective and safe, these devices may be additional nonva-
soconstrictive alternatives.
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